<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9153">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704244</url>
  </required_header>
  <id_info>
    <org_study_id>000381</org_study_id>
    <nct_id>NCT05704244</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)</brief_title>
  <official_title>A Phase 3, Open Label Trial to Evaluate the Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG&#xD;
      unresponsive NMIBC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2022</start_date>
  <completion_date type="Anticipated">December 27, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whether or not a subject with CIS (with or without concomitant high-grade Ta or T1 papillary disease) responds to treatment, defined as complete response at any time after first administration of FE 999326</measure>
    <time_frame>At Month 12 assessment</time_frame>
    <description>A subject with CIS (with or without concomitant high-grade Ta or T1 papillary disease) has achieved a complete response at an efficacy assessment if urine cytology is negative and there are no lesions on cystoscopy. If biopsy of the bladder is performed, this must be negative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response in subjects with CIS (with or without concomitant high-grade Ta or T1 papillary disease) who show a complete response at any time after first administration of FE 999326</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether or not a subject with high-grade Ta or T1 papillary disease (without concomitant CIS) responds to treatment, defined as absence of recurrence of high-grade disease</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of event-free survival in subjects with high-grade Ta or T1 papillary disease (without concomitant CIS) and in subjects with CIS (with or without papillary disease)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cystectomy</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cystectomy</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of FE 999326-specific DNA levels in urine</measure>
    <time_frame>Up to day 1 of month 4 after start of treatment; and 3, 6, 9 and 12 months after last dose (up to 5 years after start of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type, incidence, relatedness and severity of treatment emergent adverse events</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>FE 999326</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FE 999326</intervention_name>
    <description>75 mL FE 999326 (3 x 10^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter</description>
    <arm_group_label>FE 999326</arm_group_label>
    <other_name>nadofaragene firadenovec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have at entry, confirmed by a pathology report:&#xD;
&#xD;
               1. Carcinoma in situ (CIS) only&#xD;
&#xD;
               2. Ta/T1 high-grade disease with concomitant CIS or&#xD;
&#xD;
               3. Ta/T1 high-grade disease without concomitant CIS&#xD;
&#xD;
          -  Subjects who did not respond to BCG treatment and have a persistent high-grade&#xD;
             recurrence within 12 months after BCG was initiated, and those who despite an initial&#xD;
             complete response to BCG, relapse with CIS within 12 months of their last intravesical&#xD;
             treatment with BCG or relapse with high-grade Ta/T1 NMIBC within 6 months of their&#xD;
             last intravesical treatment with BCG.&#xD;
&#xD;
          -  Life expectancy &gt;2 years, in the opinion of the investigator&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) status 2 or less&#xD;
&#xD;
          -  Absence of concomitant upper tract urothelial carcinoma or urothelial carcinoma within&#xD;
             the prostatic urethra&#xD;
&#xD;
          -  Subjects with prostate cancer on active surveillance at low risk for progression,&#xD;
             defined as prostate-specific antigen (PSA) &lt;10 ng/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or previous evidence of muscle invasive (muscularis propria) or metastatic&#xD;
             disease presented at the screening visit.&#xD;
&#xD;
          -  Current systemic therapy for bladder cancer&#xD;
&#xD;
          -  Current or prior investigational treatment for BCG unresponsive NMIBC or any other&#xD;
             investigational drug within 1 month prior to screening&#xD;
&#xD;
          -  Current or prior pelvic external beam radiotherapy within 5 years of entry&#xD;
&#xD;
          -  Use of other adenovirus vector medications, including COVID-19 vaccines, within 2&#xD;
             weeks before and after instillation&#xD;
&#xD;
          -  History of malignancy of other organ system within past 5 years, except treated basal&#xD;
             cell carcinoma or squamous cell carcinoma of the skin and â‰¤pT2 upper tract urothelial&#xD;
             carcinoma at least 24 months after nephroureterectomy.&#xD;
&#xD;
          -  Subjects who cannot hold instillation for 1 hour&#xD;
&#xD;
          -  Subjects who cannot tolerate intravesical dosing or intravesical surgical manipulation&#xD;
&#xD;
          -  Intravesical therapy within 8 weeks prior to beginning trial treatment, with the&#xD;
             exception of:&#xD;
&#xD;
               -  Cytotoxic agents when administered as a single instillation immediately following&#xD;
                  a TURBT procedure&#xD;
&#xD;
               -  Previous intravesical BCG therapy&#xD;
&#xD;
          -  Systemic immunosuppressive therapy within 3 months prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 833-548-1402 (US/Canada)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 862-286-5200 (outside US)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Hakodate-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Hitachi-shi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Tsukuba-shi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Nankoku-shi</city>
        <state>Kochi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Tsu-shi</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Kashihara-shi</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Takatsuki-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring Investigational Site</name>
      <address>
        <city>Toyama-shi</city>
        <state>Toyama</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>December 21, 2022</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>May 1, 2023</last_update_submitted>
  <last_update_submitted_qc>May 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Non-Muscle Invasive Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

